CIK 0000907654
- Non-accelerated filer
- Smaller reporting company
Oruka Therapeutics, Inc.
Sign in to watch- Ticker
- ORKA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 363855489
- Phone
- +1 650-606-7910
- Business address
- 855 OAK GROVE AVE., SUITE 100, MENLO PARK, CA, 94025
- Former names
- ARCA biopharma, Inc., NUVELO INC, HYSEQ INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $21,431,111
- in 18 filings, $21.0M under 10b5-1 plans
Net −$21,431,111. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Klein Lawrence Otto −$11.6M Chief Executive Officer sold 12% of stake
- Agarwal Arjun −$2.8M Senior Vice President, Finance sold 68% of stake
- Quinlan Paul T −$2.6M General Counsel sold 49% of stake
- Goncalves Joana −$2.0M Chief Medical Officer sold 41% of stake
- BALL KRISTINE M −$1.9M Director sold 100% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2012-02-10 | FORMELA JEAN FRANCOIS Director | Grant or award · Option to Purchase Common Stock | +3,500 | 3,500 | ||
| 2011-05-20 | Wheeler Patrick M Chief Financial Officer | Grant or award · Options to Purchase Common Stock | −20,000 | 20,000 | ||
| 2011-05-20 | BRISTOW MICHAEL R President and CEO | Grant or award · Option to Purchase Common Stock | −30,000 | 30,000 | ||
| 2011-05-20 | Ozeroff Christopher David SVP and General Counsel | Grant or award · Option to Purchase Common Stock | −20,000 | 20,000 | ||
| 2010-07-07 | Ozeroff Christopher David SVP & GENERAL COUNSEL | Other disposition | −2,051 | 41,758 | ||
| 2010-07-02 | Ozeroff Christopher David SVP & GENERAL COUNSEL | Exercise or conversion | +4,101 | $0.06 | $246 | 43,809 |
| 2010-07-02 | Ozeroff Christopher David SVP & GENERAL COUNSEL | Exercise or conversion · Option to purchase Common Stock | +4,101 | 0 | ||
| 2010-05-26 | Ozeroff Christopher David SVP & GENERAL COUNSEL | Other disposition | −39,709 | 39,708 | ||
| 2010-03-29 | Atlas Venture Fund VII L P 10% owner | Sale | −140,000 | $7.56 | $1.1M | 1,337,612 |
| 2010-03-29 | FORMELA JEAN FRANCOIS Director | Sale | −140,000 | $7.56 | $1.1M | 1,337,612 |
| 2010-03-29 | Grais Linda S Director | Sale | −23,600 | $7.98 | $188K | 679,098 |
| 2010-03-29 | Grais Linda S Director | Sale | −187,209 | $7.30 | $1.4M | 491,889 |
| 2010-02-18 | BRISTOW MICHAEL R President and CEO | Grant or award · Option to Purchase Common Stock | +16,000 | 16,000 | ||
| 2010-02-18 | Wheeler Patrick M acting Chief Financial Officer | Grant or award · Option to Purchase Common Stock | +6,400 | 6,400 | ||
| 2010-02-18 | Ozeroff Christopher David SVP & GENERAL COUNSEL | Grant or award · Option to Purchase Common Stock | +6,400 | 6,400 | ||
| 2010-02-05 | SOBEL BURTON E Director | Grant or award · Option to Purchase Common Stock | +3,500 | 3,500 | ||
| 2010-02-05 | FORMELA JEAN FRANCOIS Director | Grant or award · Option to Purchase Common Stock | +3,500 | 3,500 | ||
| 2010-02-05 | ZABRISKIE JOHN L Director | Grant or award · Option to Purchase Common Stock | +3,500 | 3,500 | ||
| 2010-02-05 | Grais Linda S Director | Grant or award · Option to Purchase Common Stock | +3,500 | 3,500 | ||
| 2010-02-05 | PENDERGAST MARY K Director | Grant or award · Option to Purchase Common Stock | +3,500 | 3,500 |
Page 28 of 41 · 802 trades